Case Report: Zanubrutinib for refractory immune thrombotic thrombocytopenic purpura
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) results from severe ADAMTS13 deficiency and may relapse despite modern therapy, with survival exceeding 95% in contemporary cohorts. We report the case of a 43-year-old patient with multiple cl…